We have a suspicion that you are an automated web bot software, not a real user.
To keep our site fast for other users, we have slowed down this page.
The slowdown will gradually disappear.
If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu.
Also note that all data for hgGeneGraph can be obtained through our public MySQL server and
all our software source code is available and can be installed locally onto your own computer.
If you are unsure how to use these resources, do not hesitate to contact us.
Hidalgo et al., Semin Oncol 2003
:
Phase I pharmacokinetic studies show that treatment with erlotinib HCl ( Tarceva ; Genentech Inc, South San Francisco, CA ), an orally available epidermal growth factor receptor ( HER1/EGFR ) -tyrosine kinase inhibitor , on a daily, uninterrupted schedule is feasible
Gordon et al., Int J Gynecol Cancer 2005
(Ovarian Neoplasms) :
Efficacy and safety of erlotinib HCl , an epidermal growth factor receptor ( HER1/EGFR ) tyrosine kinase inhibitor , in patients with advanced ovarian carcinoma : results from a phase II multicenter study